Phase 2 × Completed × Leukemia, Myelomonocytic, Chronic × Clear all
NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled 15 charts
NCT01760655 2025-10-30

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
62 enrolled 15 charts
NCT02566304 2025-04-24

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
35 enrolled 14 charts
NCT03096782 2023-10-11

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
6 enrolled 10 charts
NCT00045305 2023-06-28

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Eastern Cooperative Oncology Group

Phase 2 Completed
17 enrolled 10 charts
NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
117 enrolled 27 charts
NCT00860574 2021-06-22

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
96 enrolled 15 charts
NCT00489203 2021-02-03

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
140 enrolled
NCT00005797 2020-12-10

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
125 enrolled
NCT00309842 2020-09-10

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
213 enrolled 19 charts
NCT00053989 2020-02-10

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Roswell Park Cancer Institute

Phase 2 Completed
41 enrolled 13 charts
NCT00397813 2020-01-31

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Fred Hutchinson Cancer Center

Phase 2 Completed
77 enrolled 16 charts
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT01093586 2019-01-23

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 2 Completed
14 enrolled 22 charts
NCT00425477 2018-10-05

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
26 enrolled 7 charts
NCT00134017 2018-08-31

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
142 enrolled 11 charts
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts
NCT00462605 2017-07-18

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
24 enrolled 5 charts
NCT00691015 2017-06-28

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
48 enrolled 12 charts
NCT00118352 2017-05-30

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
12 enrolled 10 charts